Martin Stangel1, Iris Katharina Penner2, Boris A Kallmann3, Carsten Lukas4, Bernd C Kieseier5. 1. Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. 2. Cognitive Psychology and Methodology, University of Basel, Basel, Switzerland. 3. Multiple-Sclerosis-Center Franken, Bamberg, Germany. 4. Institute for Diagnostic and Interventional Radiology, St Josef Hospital, Ruhr-University Bochum, Germany. 5. Department of Neurology Medical Faculty, Heinrich-Heine University Düsseldorf, Germany.
Abstract
OBJECTIVE: The introduction of new and potent therapies for the treatment of relapsing remitting multiple sclerosis (MS) has increased the desire for therapeutic success. There is growing doubt that the mere reduction of relapse rate, Expanded Disability Status Scale (EDSS) progression and magnetic resonance imaging (MRI) markers are exclusive and appropriate factors to monitor the new aim of 'no evidence of disease activity' (NEDA). However, there is no generally accepted definition so far. METHODS: To achieve the therapeutic aim of NEDA, a panel of MS experts searched the available literature on clinical and paraclinical outcomes to propose a test battery that is sensitive to detect disease activity in an everyday clinical setting. RESULTS: The panel proposed to include, besides relapse rate, disability progression and MRI, neuropsychological outcome measures such as cognitive status, fatigue, depression and quality of life. To standardize the examinations in an economic and schematic way, a multifactorial model [multiple sclerosis decision model (MSDM)] that includes the domains 'relapse', 'disability progression', 'MRI', and 'neuropsychology' is proposed. The scheme reflects the complexity of the disease even in the early stages when scales such as the EDSS are not able to distinguish low levels of progression. CONCLUSION: The MSDM aims to support early treatment decisions and uncover timely treatment failure. Prospective investigations are required to prove that such a disease-monitoring concept leads to an early and effective silencing of disease activity.
OBJECTIVE: The introduction of new and potent therapies for the treatment of relapsing remitting multiple sclerosis (MS) has increased the desire for therapeutic success. There is growing doubt that the mere reduction of relapse rate, Expanded Disability Status Scale (EDSS) progression and magnetic resonance imaging (MRI) markers are exclusive and appropriate factors to monitor the new aim of 'no evidence of disease activity' (NEDA). However, there is no generally accepted definition so far. METHODS: To achieve the therapeutic aim of NEDA, a panel of MS experts searched the available literature on clinical and paraclinical outcomes to propose a test battery that is sensitive to detect disease activity in an everyday clinical setting. RESULTS: The panel proposed to include, besides relapse rate, disability progression and MRI, neuropsychological outcome measures such as cognitive status, fatigue, depression and quality of life. To standardize the examinations in an economic and schematic way, a multifactorial model [multiple sclerosis decision model (MSDM)] that includes the domains 'relapse', 'disability progression', 'MRI', and 'neuropsychology' is proposed. The scheme reflects the complexity of the disease even in the early stages when scales such as the EDSS are not able to distinguish low levels of progression. CONCLUSION: The MSDM aims to support early treatment decisions and uncover timely treatment failure. Prospective investigations are required to prove that such a disease-monitoring concept leads to an early and effective silencing of disease activity.
Authors: H L Weiner; C R Guttmann; S J Khoury; E J Orav; M J Hohol; R Kikinis; F A Jolesz Journal: J Neuroimmunol Date: 2000-05-01 Impact factor: 3.478
Authors: M P Sormani; J Rio; M Tintorè; A Signori; D Li; P Cornelisse; B Stubinski; M l Stromillo; X Montalban; N De Stefano Journal: Mult Scler Date: 2012-09-25 Impact factor: 6.312
Authors: Antonio Scalfari; Anneke Neuhaus; Alexandra Degenhardt; George P Rice; Paolo A Muraro; Martin Daumer; George C Ebers Journal: Brain Date: 2010-06-09 Impact factor: 13.501
Authors: Mark S Freedman; Daniel Selchen; Douglas L Arnold; Alexandre Prat; Brenda Banwell; Michael Yeung; David Morgenthau; Yves Lapierre Journal: Can J Neurol Sci Date: 2013-05 Impact factor: 2.104
Authors: Eva Havrdova; Steven Galetta; Michael Hutchinson; Dusan Stefoski; David Bates; Chris H Polman; Paul W O'Connor; Gavin Giovannoni; J Theodore Phillips; Fred D Lublin; Amy Pace; Richard Kim; Robert Hyde Journal: Lancet Neurol Date: 2009-02-07 Impact factor: 44.182
Authors: Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman Journal: Nat Rev Neurol Date: 2015-09-15 Impact factor: 42.937
Authors: Maria Trojano; Mar Tintore; Xavier Montalban; Jan Hillert; Tomas Kalincik; Pietro Iaffaldano; Tim Spelman; Maria Pia Sormani; Helmut Butzkueven Journal: Nat Rev Neurol Date: 2017-01-13 Impact factor: 42.937
Authors: M Cabezas; J F Corral; A Oliver; Y Díez; M Tintoré; C Auger; X Montalban; X Lladó; D Pareto; À Rovira Journal: AJNR Am J Neuroradiol Date: 2016-06-09 Impact factor: 3.825